Tag: Clarity Pharmaceuticals
Clarity and Nucleus RadioPharma scale up manufacturing for cancer treatment
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has entered into a Master Services Agreement (MSA) and Clinical Manufacturing Agreement for the production of 67Cu-SAR-bisPSMA, a radiopharmaceutical treatment for prostate cancer.Â
Clarity Pharmaceuticals inks clinical supply agreement for prostate cancer imaging products
ASX-listed Clarity Pharmaceuticals has signed a Master Service Agreement and a Clinical Supply Agreement with Siemens Healthineers company PETNET Solutions Inc for the supply expansion of Clarity’s 64Cu SAR-bisPSMA, a diagnostic radiopharmaceutical product for prostate cancer imaging.
Featured Article
Unlocking growth: Charting midsize manufacturers’ path with digital solutions
According to a recent study by Oxford Economics, midsized companies in the industrial manufacturing sector are setting their eyes on ambitious growth targets. The research, authored in partnership with SAP, revealed that 38% of industry leaders have identified market expansion as their top priority.
